Literature DB >> 27185540

First metabolic profile of PV8, a novel synthetic cathinone, in human hepatocytes and urine by high-resolution mass spectrometry.

Madeleine J Swortwood1, Kayla N Ellefsen1,2, Ariane Wohlfarth1,3,4, Xingxing Diao1, Marta Concheiro-Guisan1,5, Robert Kronstrand3,4, Marilyn A Huestis6,7.   

Abstract

Novel psychoactive substances (NPS) are ever changing on the drug market, making it difficult for toxicology laboratory methods to stay current with so many new drugs. Recently, PV8, a synthetic pyrrolidinophenone, was detected in seized products in Japan (2013), The Netherlands (2014), and Germany (2014). There are no controlled PV8 administration studies, and no pharmacodynamic and pharmacokinetic data. The objective was to determine PV8's metabolic stability in human liver microsome (HLM) incubation and its metabolism following human hepatocyte incubation and high-resolution mass spectrometry (HRMS) with a Thermo Scientific Q-Exactive. Data were acquired with a full-scan data-dependent mass spectrometry method. Scans were thoroughly data mined with different data processing algorithms and analyzed in WebMetaBase. PV8 exhibited a relatively short 28.8 min half-life, with an intrinsic 24.2 μL/min/mg microsomal clearance. This compound is predicted to be an intermediate clearance drug with an estimated human 22.7 mL/min/kg hepatic clearance. Metabolic pathways identified in vitro included: hydroxylation, ketone reduction, carboxylation, N-dealkylation, iminium formation, dehydrogenation, N-oxidation, and carbonylation. The top three in vitro metabolic pathways were di-hydroxylation > ketone reduction > γ-lactam formation. Authentic urine specimen analyses revealed the top three metabolic pathways were aliphatic hydroxylation > ketone reduction + aliphatic hydroxylation > aliphatic carboxylation, although the most prominent peak was parent PV8. These data provide useful urinary metabolite targets (aliphatic hydroxylation, aliphatic hydroxylation + ketone reduction, aliphatic carboxylation, and di-hydroxylation) for forensic and clinical testing, and focus reference standard companies' synthetic efforts to provide commercially available standards needed for PV8 biological specimen testing. Graphical Abstract Top four PV8 metabolites identified in vitro. Biotransformations highlighted in blue. Markush structures presented when exact location of biotransformation is unknown.

Entities:  

Keywords:  HRMS; Hepatocytes; Metabolic profiling; Novel psychoactive substances; PV8; Synthetic cathinones

Mesh:

Substances:

Year:  2016        PMID: 27185540     DOI: 10.1007/s00216-016-9599-4

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  8 in total

1.  Identification of New Synthetic Cannabinoid ADB-CHMINACA (MAB-CHMINACA) Metabolites in Human Hepatocytes.

Authors:  Jeremy Carlier; Xingxing Diao; Cristina Sempio; Marilyn A Huestis
Journal:  AAPS J       Date:  2017-01-09       Impact factor: 4.009

2.  Polydrug abuse among opioid maintenance treatment patients is related to inadequate dose of maintenance treatment medicine.

Authors:  Pertti Kalevi Heikman; Leea Hellevi Muhonen; Ilkka Antero Ojanperä
Journal:  BMC Psychiatry       Date:  2017-07-06       Impact factor: 3.630

3.  Toxicometabolomics of the new psychoactive substances α-PBP and α-PEP studied in HepaRG cell incubates by means of untargeted metabolomics revealed unexpected amino acid adducts.

Authors:  Sascha K Manier; Lea Wagmann; Veit Flockerzi; Markus R Meyer
Journal:  Arch Toxicol       Date:  2020-04-20       Impact factor: 5.153

4.  Untargeted metabolomics by high resolution mass spectrometry coupled to normal and reversed phase liquid chromatography as a tool to study the in vitro biotransformation of new psychoactive substances.

Authors:  Sascha K Manier; Andreas Keller; Jan Schäper; Markus R Meyer
Journal:  Sci Rep       Date:  2019-02-26       Impact factor: 4.379

5.  Metabolic Profile of Four Selected Cathinones in Microsome Incubations: Identification of Phase I and II Metabolites by Liquid Chromatography High Resolution Mass Spectrometry.

Authors:  Beatriz T Lopes; Maria João Caldeira; Helena Gaspar; Alexandra M M Antunes
Journal:  Front Chem       Date:  2021-01-12       Impact factor: 5.221

6.  Untargeted Metabolic Profiling of 4-Fluoro-Furanylfentanyl and Isobutyrylfentanyl in Mouse Hepatocytes and Urine by Means of LC-HRMS.

Authors:  Camilla Montesano; Flaminia Vincenti; Federico Fanti; Matteo Marti; Sabrine Bilel; Anna Rita Togna; Adolfo Gregori; Fabiana Di Rosa; Manuel Sergi
Journal:  Metabolites       Date:  2021-02-10

7.  Protective Effect of Aldo-keto Reductase 1B1 Against Neuronal Cell Damage Elicited by 4'-Fluoro-α-pyrrolidinononanophenone.

Authors:  Yoshifumi Morikawa; Hidetoshi Miyazono; Kyoko Kamase; Koichi Suenami; Yasuhide Sasajima; Kiyohito Sato; Satoshi Endo; Yasunari Monguchi; Yuji Takekoshi; Akira Ikari; Toshiyuki Matsunaga
Journal:  Neurotox Res       Date:  2021-05-27       Impact factor: 3.911

8.  Metabolism of α-PHP and α-PHPP in humans and the effects of alkyl chain lengths on the metabolism of α-pyrrolidinophenone-type designer drugs.

Authors:  Shuntaro Matsuta; Noriaki Shima; Hidenao Kakehashi; Hiroe Kamata; Shihoko Nakano; Keiko Sasaki; Tooru Kamata; Hiroshi Nishioka; Akihiro Miki; Kei Zaitsu; Hitoshi Tsuchihashi; Munehiro Katagi
Journal:  Forensic Toxicol       Date:  2018-05-28       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.